Shares of PTC Therapeutics (PTCT) are down $1.99 to $58.58 in early trading.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTCT:
- PTC Therapeutics participates in a conference call with Truist
- PTC Therapeutics Completes Study on Vatiquinone for Friedreich Ataxia in Young Children
- PTC Therapeutics price target lowered to $71 from $76 at Morgan Stanley
- PTC Therapeutics: Buy Rating Affirmed Amid Temporary Weakness and Promising Pipeline
- JPMorgan adds PTC Therapeutics to Analyst Focus List after selloff